Skip to main content
DaVitaRevenue

DaVita (DVA) Reports Q2: Everything You Need To Know Ahead Of Earnings

What happened

DaVita reported revenues of $3.42 billion in the previous quarter, an increase of 6% year-on-year.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting earnings this Tuesday afternoon. Here's what you need to know. DaVita beat analysts' revenue expectations last quarter, reporting revenues of $3.42 billion, up 6% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates. Is DaVita a buy or sell going into earnings? Read our full analysis here, it's free for active Edge members. This quarter, the market is expecting DaVita's revenue to grow 3.5% year on year, slowing from the 6.1% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. DaVita rarely misses Wall Street's revenue estimates. Looking at DaVita's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 9.9%, beating analysts' expectations by 13.1%, and Tenet Healthcare reported revenues up 6.8%, topping estimates by 3.9%. Centene traded down 3.5% following the results while Tenet Healthcare was up 17.2%. Read our full analysis of Centene's results here and Tenet Healthcare's results here...

Keep reading with a free account

The rest of this article, and every signal for DaVita, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$3.4B

More revenue signals at other companies

The full record

From the Signal API record

Numbers

Amount named in the story
$3.4B

Extraction

Confidence
90%
Detected
Aug 3, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for DaVita and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at DaVita this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/cb2b3a4d-4541-3dec-e5f8-ed889e510290 returns this record as JSON. POST /v1/companies/enrich returns every signal for davita.com.

{
  "signal_id": "cb2b3a4d-4541-3dec-e5f8-ed889e510290",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-08-03T03:46:19+00:00",
  "company": {
    "name": "DaVita",
    "domain": "davita.com"
  },
  "data": {
    "url": "https://stockstory.org/us/stocks/nyse/dva/news/earnings/davita-dva-reports-q2-everything-you-need-to-know-ahead-of-earnings",
    "title": "DaVita (DVA) Reports Q2: Everything You Need To Know Ahead Of Earnings - StockStory",
    "excerpt": "Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting earnings this Tuesday afternoon. Here’s what you need to know. DaVita beat analysts’ revenue expectations last quarter, reporting revenues of $3.42 billion, up 6% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates. Is DaVita a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members . This quarter, the market is expecting DaVita’s revenue to grow 3.5% year on year, slowing from the 6.1% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. DaVita rarely misses Wall Street’s revenue estimates. Looking at DaVita’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 9.9%, beating analysts’ expectations by 13.1%, and Tenet Healthcare reported revenues up 6.8%, topping estimates by 3.9%. Centene traded down 3.5% following the results while Tenet Healthcare was up 17.2%. Read our full analysis of Centene’s results here and Tenet Healthcare’s results here . Investors...",
    "summary": "DaVita reported revenues of $3.42 billion in the previous quarter, an increase of 6% year-on-year.",
    "planning": false,
    "image_url": "https://stockstory.org/stockstory/company-image/DVA",
    "confidence": 0.9,
    "published_at": "2026-08-03T03:46:19Z",
    "article_sentence": "DaVita beat analysts’ revenue expectations last quarter, reporting revenues of $3.42 billion, up 6% year on year.",
    "amount_normalized": 3420000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.